Abstract:Mucopolysaccharidoses (MPS) are lysosomal storage diseases caused by defects in catabolism of glycosaminoglycans. MPS I, II, III and VII are associated with lysosomal accumulation of heparan sulphate and manifest with neurological deterioration. Most of these neurological MPS currently lack effective treatments. Here, we report that, compared to controls, neuraminidase 1 (NEU1) activity is drastically reduced in brain tissues of neurological MPS patients and in mouse models of MPS I, II, IIIA, IIIB and IIIC, but not of other neurological lysosomal disorders not presenting with heparan sulphate storage. We further show that accumulated heparan sulphate disrupts the lysosomal multienzyme complex of NEU1 with cathepsin A (CTSA), β-galactosidase (GLB1) and glucosamine-6-sulfate sulfatase (GALNS) necessary to maintain enzyme activity, and that NEU1 deficiency is linked to partial deficiencies of GLB1 and GALNS in cortical tissues and iPSC-derived cortical neurons of neurological MPS patients. Increased sialylation of N-linked glycans in brain samples of human MPS III patients and MPS IIIC mice implicated insufficient processing of brain N-linked sialylated glycans, except for polysialic acid, which was reduced in the brains of MPS IIIC mice. Correction of NEU1 activity in MPS IIIC mice by lentiviral gene transfer ameliorated previously identified hallmarks of the disease, including memory impairment, behavioural traits, and reduced levels of the excitatory synapse markers VGLUT1 and PSD95. Overexpression of NEU1 also restored levels of VGLUT1-/PSD95-positive puncta in cortical neurons derived from iPSC of an MPS IIIA patient. Together, our data demonstrate that heparan sulphate-induced secondary NEU1 deficiency and aberrant sialylation of glycoproteins implicated in synaptogenesis, memory, and behaviour constitute a novel pathological pathway in neurological MPS spectrum crucially contributing to CNS pathology.

Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent

Severe kidney dysfunction in sialidosis mice reveals an essential role for neuraminidase 1 in reabsorption

Compound Heterozygous Mutations in the Neuraminidase 1 Gene in Type 1 Sialidosis: A Case Report and Review of Literature

Gene therapy corrects the neurological deficits of mice with sialidosis

Secondary deficiency of neuraminidase 1 contributes to CNS pathology in neurological mucopolysaccharidoses via hypersialylation of brain glycoproteins

Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Defect in cytosolic Neu2 sialidase abrogates lipid metabolism and impairs muscle function in vivo

Neuraminidase-1: A Sialidase Involved in the Development of Cancers and Metabolic Diseases

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

Glutaminase 1 is essential for the differentiation, proliferation, and survival of human neural progenitor cells.

Existence of NEU1 sialidase on mouse thymocytes whose natural substrate is CD5

NEU1 and NEU3 Sialidase Activity Expressed in Human Lung Microvascular Endothelia

Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes

GNE deficiency impairs Myogenesis in C2C12 cells and cannot be rescued by ManNAc supplementation

The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection

Evaluation of N-Acetylmannosamine Administration to Restore Sialylation in GNE-Deficient Human Embryonal Kidney Cells

New Insights into Molecular Organization of Human Neuraminidase-1: Transmembrane Topology and Dimerization Ability

Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond